NCT01232348已完成不适用
Symbicort Turbuhaler 30/60 Clinical Experience Investigation
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 3,643
- 试验地点
- 1
- 主要终点
- Incidence of Adverse Events
研究概览
简要总结
The purpose of this study is to confirm the safety (ADR related to beta stimulant drugs, unexpected ADRs) and efficacy of Symbicort in daily practice and the control status on bronchial asthma and Patient satisfaction
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients treated with Symbicort for the first time due to bronchial asthma
排除标准
- 未提供
结局指标
主要结局
Incidence of Adverse Events
时间窗: Range of 12 weeks
次要结局
- The level of asthma control(Range of 12 weeks)
- The level of patient satisfaction with Symbicort(Range of 12 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever TherapyBronchial AsthmaNCT01711840AstraZeneca2,409
已完成
不适用
Symbicort Turbuhaler 30/60 Specific Clinical Experience InvestigationBronchial AsthmaNCT01232335AstraZeneca1,500
已完成
不适用
Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for Chronic Obstructive Pulmonary Disease (COPD) PatientsChronic Obstructive Pulmonary DiseaseNCT01713075AstraZeneca1,183
已完成
3 期
A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With AsthmaAsthmaNCT02224157AstraZeneca4,215
已完成
3 期
Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mgAsthmaNCT00242775AstraZeneca2,100